No Data
No Data
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 12.66%. Currently, Regeneron Pharmaceut
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,183
Morgan Stanley analyst Terence Flynn maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,183.According to TipRanks data, the analyst has a success ra
Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characteriz
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Wednesday the European Commission has approved Dupixent as an additional maintenance treatment for adults with uncontrolled chronic obstructive p
RDK79 : I recognized one word in that lead sentence:)))
But it sounds like good news!!!